1. A position statement on NAFLD/NASH based on the EASL 2009 special conference / V. Ratziu [et al.] // J. Hepatol. - 2010. - Vol. 53, N 2. - P. 372-384.
2. Serum markers of liver fibrosis in patients with non-alcocholic steatohepatitis (NASH). Correlation to morphology and effect of therapy / J. Holoman [et al.] // J. Hepatol. - 2000. - Vol. 32. - Р. 210.
3. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice / E. Halilbasic [et al.] // J. Hepatol. - 2009. - Vol. 49. - P. 1972-1981.
4. Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis / V. Buko [et al.] // J. Clin. Exp. Hepatol. - 2014. - Vol. 4, N 4. - P. 293-301.
5. Model of nonalcoholic steatohepatitis / C. S. Lieber [et al.] // Am. J. Clin. Nutr. - 2004. - Vol. 79. - P. 502-509.
6. The autooxidation of human red cells lipids induced by hydrogen peroxide / J. Stocks [et al.] // Br. J. Haematol. - 1971. - Vol. 20, N 1. - P. 95-111.
7. A new and rapid colorimetric determination of acetylcholinesteraze activity / G. L. Ellman [et al.] // Biochem. Pharmacol. - 1961. - Vol. 7. - P. 88-95.
8. A sensitive microassay for the determination of glutathione peroxidase activity. Application to human blood platelets / J. I. R. Martinez [et al.] // Anal. Biochem. - 1979. - Vol. 98. - P. 154-159.
9. Effect of riboflavin depletion and repletion on the erythrocyte glutathione reductase in the rat / J. A. Tilbotson [et al.] // J. Nutrition. - 1971. - Vol. 101. - P. 1459-1466.
10. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers / R. Müller- Peddinhaus [et al.] // Biochem. Pharmacol. - 1987. - Vol. 36. - P. 1125-1132.
11. Nonsuperoxide lucigenin-enhanced chemiluminescence from phospholipids and human saphenous veins / D. A. Barber [et al.] // Free Radic. Biol. Med. - 1995. - Vol. 18, N 3. - P. 565-569.
12. Профилактическое применение новых производных урсодезоксихолевой кислоты при экспериментальном алкогольном стеатогепатите / Е. Б. Белоновская [и др.] // Эксперим. и клин. фармакология. - 2013. - Т. 76, № 1. - С. 25-29.
13. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis / N. Beraza [et al.] // Gut. - 2011. - Vol. 60. - P. 387-396.
14. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans / A. F. Hofmann [et al.] // Hepatology. - 2005. - Vol. 42. - P. 1391-1398.
15. Differing effect of nor-ursodeoxycholic and ursodeoxycholic acid on hepatic histology and bile acid metabolism in rabbit / B. I. Cohen [et al.] // Gastroenterology. - 1986. - Vol. 91. - P. 189-197.
16. 24-nor-ursodeoxycholic acid as novel therapeutic strategy for inflammation-induced liver fibrosis in a murine model of Shisostoma mansoni infection / M. Sombetzky [et al.] // J. Hepatol. - 2008. - Vol. 48, N 2. - P. 21-22.